Shares of Niagen Bioscience, Inc. (NASDAQ: NAGE) surged approximately 38% after the company reported better-than-expected fourth-quarter results, driven by strong revenue growth and expanding demand…
The global chronic kidney disease (CKD) market is expected to expand steadily over the next decade as rising disease prevalence, earlier diagnosis, and continued pharmaceutical…
Esperion Therapeutics (NASDAQ: ESPR) has announced a definitive agreement to acquire Corstasis Therapeutics, adding Enbumyst™ bumetanide nasal spray, the first and only FDA-approved intranasal loop…
Rallybio Corporation (NASDAQ: RLYB) has agreed to merge with privately held Candid Therapeutics in a reverse merger that will create a newly capitalized, Nasdaq-listed biotech…
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has expanded its rare disease portfolio through the acquisition of U.S. commercialization rights to HEMANGEOL®, the only FDA-approved oral treatment…
Shares of Intellia Therapeutics (NASDAQ: NTLA) moved higher after the U.S. Food and Drug Administration lifted a clinical hold on the company’s Phase 3 gene-editing…
February 26, 2026
Investing in Innovation during Rare Disease Day 2026
Rare Disease Day 2026 serves as a powerful reminder of the urgent, high-stakes innovation occurring across the biotechnology landscape. For companies like Larimar Therapeutics (NASDAQ:…
February 26, 2026
Vir Biotechnology Stock Drops Following Discounted Share Offering
Vir Biotechnology Inc. (NASDAQ: VIR) shares plunged 16% on Thursday after the company revealed the pricing details of its underwritten public offering. The offering, priced…
February 24, 2026
Cancer Immunotherapy Breakthroughs Are Transforming Oncology and Driving Biotech Growth
Cancer immunotherapy has become one of the most important breakthroughs in modern medicine, reshaping how cancer is treated and creating significant commercial opportunities for leading…
February 23, 2026
Bora Pharmaceuticals Secures $250 Million Manufacturing Deal with GSK, Expanding Long-Term Revenue Visibility
Bora Pharmaceuticals Co., Ltd. (OTCQX: BORAY) has signed a five-year global manufacturing agreement valued at approximately $250 million with GSK plc (NYSE: GSK), strengthening its…
February 20, 2026
Biotech Breakthrough: Revyve Outperforms Silver Standards in Study
Kane Biotech Inc. (OTCQB: KNBIF) recently announced the publication of pivotal clinical data regarding its Revyve Antimicrobial Wound Gel. The Journal of Wound Care published…
February 19, 2026
GE HealthCare Secures Three FDA Clearances for Next-Generation SIGNA MRI Systems and AI Imaging Platform
GE HealthCare (NASDAQ: GEHC) has received three FDA clearances for its next-generation SIGNA MRI technologies, expanding its advanced imaging portfolio and reinforcing its leadership in…